Nkarta (NKTX) Earnings Date & Reports

Key Takeaways

• Nkarta reported a third-quarter 2026 net loss of $33.33 million, compared with $21.72 million in the same period a year earlier.
• Loss per share widened to $0.45 from $0.29, coming in below the Wall Street consensus estimate of roughly $0.40.
• The clinical-stage biotech recorded no product revenue, making cash burn and operating expenses the key financial focus.
• The company's pipeline centerpiece remains NKX019, an off-the-shelf CAR NK cell therapy for autoimmune diseases, with initial clinical data expected at a 2026 medical conference.
• For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover automated trading ideas and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Because it has no commercialized products, its quarterly earnings reports are less about top-line revenue and more about two things: the pace of cash consumption and the clinical progress of its lead candidate, NKX019. That program, a chimeric antigen receptor NK (CAR NK) therapy targeting the CD19 antigen, is being studied in autoimmune diseases through the Ntrust-1 and Ntrust-2 trials. For investors, each report offers a checkpoint on spending discipline, balance-sheet runway, and whether the company remains on track to deliver meaningful clinical data that could reshape its valuation.

Reported Results

For the third quarter ended September 30, 2026, Nkarta reported a net loss of $33.33 million, up from $21.72 million in the prior-year quarter. Basic and diluted loss per share from continuing operations was $0.45, compared with $0.29 a year earlier. The result came in wider than the analyst consensus estimate, which was around $0.40 per share.

For the first nine months of 2026, the company posted a net loss of $101.53 million, versus $76.68 million in the same period of 2025, with a basic and diluted loss per share of $1.36 compared with $1.04. As expected for a pre-commercial biotech, Nkarta reported no product revenue for the quarter. The widening loss reflects higher spending tied to advancing its clinical pipeline rather than any revenue shortfall.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those monitoring clinical-stage biotechs like Nkarta, it can be a useful way to surface similar setups and track sector-wide momentum.

Market Reaction and Investor Sentiment

Investor attention around Nkarta has remained tied to clinical execution rather than headline earnings figures. As a development-stage company, a wider-than-expected loss tends to matter less than the trajectory of its NKX019 autoimmune program. The stock has a modest market capitalization and a heavy short-interest profile, which can amplify volatility around data announcements and financing headlines. The company's commentary on community-based trial enrollment and its decision to concentrate on a narrower set of indications—particularly myositis and scleroderma—has shaped sentiment by suggesting a more focused path toward later-stage development.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the initial clinical data from the Ntrust-1 and Ntrust-2 trials, which management has said it expects to present at a medical conference in 2026. Investors will be watching for efficacy signals in autoimmune diseases and, just as critically, the safety and tolerability profile that could differentiate an NK cell approach from autologous CAR T therapies.

Balance-sheet discipline is another key factor. As of June 30, 2026, Nkarta reported cash, cash equivalents, and investments of $243.2 million, which management has stated is expected to fund operations into 2029. Continued spending growth will be scrutinized against that runway, particularly as the company narrows its focus to indications it believes it can advance toward Phase 3 studies without immediately needing to raise capital.

Finally, watch for updates on indication prioritization, trial enrollment trends, and any strategic decisions around the company's broader pipeline, including its earlier-stage NKX101 program. These operational signals are likely to carry more weight for the stock than the magnitude of any single quarterly net loss.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations